Inhibiting AKT and mTOR signaling have proven beneficial in preventing HCC progression not only by abrogating VEGF secretion but also by modulating the expression of other angiogenic factors such as nitric oxide and angiopoietins (49, 50). This evidence concerns the gene VEGFA and hepatocellular carcinoma.